Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations
Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease
Objective: The clinical diagnosis of PD is based on demonstration of major motor manifestations on the neurologic exam, however, levodopa-responsiveness can be a very helpful…Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center
Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson’s Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up
Objective: The aim of the study is to assess the evolution of motor symptoms (MS), non-motor symptoms (NMS) and neuropsychological functions (NF) in Parkinson's disease…Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease
Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model
Objective: This investigation centers on the potential influence of microgravity on α-synuclein aggregation, a hallmark feature of Parkinson's disease (PD) characterized by the formation of…Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease
Objective: We attempted to identify a metabolomic signature distinctive of Parkinson’s disease (PD) through an untargeted metabolomics approach. Background: Using an high-performance liquid chromatography targeted…The Impact of Drug Interactions on the results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes
Objective: This study was a retrospective chart review of patients who underwent DAT-SPECT imaging for parkinsonism while on drugs listed as potentially interacting with the…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 338
- Next Page »